Castle’s DecisionDx-SCC Test Significantly Improves Prediction Accuracy of Metastatic Events After Mohs Surgery in Patients With High-Risk SCC of the Head and Neck
Castle Biosciences, Inc.’s DecisionDx-SCC test can improve prediction accuracy of metastatic events after Mohs surgery in patients with high-risk cutaneous squamous cell carcinoma (SCC) tumors on the head and neck, according to a study presented at the 56th American College of Mohs Surgery (ACMS) Annual Meeting in Phoenix, AZ. DecisionDx-SCC is a 40-gene expression profile […]